The prevention of neural tube defects

Current Opinion in Obstetrics and Gynecology

Volumn 10, Issue 2, 1998, Pages 85-89

  Daly, Sean ^a   Scott, John M ^b  

^a THOMAS JEFFERSON UNIVERSITY   (United States)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALPHA FETOPROTEIN; CYANOCOBALAMIN; CYSTATHIONINE BETA SYNTHASE; FOLIC ACID; HOMOCYSTEINE; METHIONINE;

AWARENESS; DIET SUPPLEMENTATION; ERYTHROCYTE LEVEL; HEALTH EDUCATION; HUMAN; NEURAL TUBE DEFECT; PREGNANCY; PRIORITY JOURNAL; REVIEW; SCREENING; SPONTANEOUS ABORTION;

FEMALE; FOLIC ACID; FOOD, FORTIFIED; HUMANS; MASS SCREENING; METHYLATION; NEURAL TUBE DEFECTS; PREGNANCY; RISK;

EID: 0031897395     PISSN: 1040872X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001703-199804000-00002     Document Type: Review

References (29)

1. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991; 338:131-137.
2. Czeizel AE, Dudas I. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832-1835,
3. Expert Advisory Group. Folic acid and the prevention of neural tube defects. London: Department of Health; 1992.
4. Centers for Disease Control. Recommendations for the use of folic acid to prevent the numbers of cases of spina bifida and other neural tube defects. MMWR 1992; 41:1-7.
5. Clark NAC, Fisk NM. Compliance with the Department of Health recommendations: routine folate prophylaxsis to prevent fetal neural tube defects. Br J Obstet Gynaecol 1994; 101:709-710.
6. Knowledge and use of folic acid by women of childbearnig age - United • States MMWR 1997; 46:721-723. This study reviews the current state of knowledge about folic acid among US women.
7. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG, et al. A candidate genetic risk factor for vascular disease: a common mutation methylene tetrahydrofolate reductase. Nature Genet 1995; 10:111-113.
8. Whitehead AS, Gallagher P, Mill JL, Kirke PN, Burke H, Molloy AM, et al. A genetic defect in 5 10-methylenetetrahydrofolate reductase in neural-tube defects. Q J Med 1995; 88:763-766.
9. van der Put NMJ, Steegers-Theunissen RPM, Frosst P, Trijbels FJM, Eskes TKAB, van den Heuvel LP, et al. Mutated methylenetetrahy-drofolate reductase as a risk factor for spina bifida. Lancet 1995; 346:1070-1071.
10. Molloy AM, Daly S, Mills JL, Kirke PN, Whitehead AS, Ramsbottom D, et •• al. Thermolabile variant of 5′10-methylenetetrahydrofolate reductase associated with low red-cell folates: implications for folate intake recommendations. Lancet 1997; 349:1591-1593. This study demonstrates that MTHFR is associated with low folate levels.
11. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 1993; 86:703-708.
12. Steegers-Theunissen R, Boers G, Trijbels FJ, Eskes TK. Neural tube defects and derangement of homocysteine metabolism [letter], N Engl J Med 1991; 324:199-200.
13. Steegers-Theunissen RPM, Boers GHJ, Trijbels FJM, Finkelstein JD, Blom HJ, Thomas CMG, et al. Maternal hyperhomocysteinemia: a risk factor for neural-tube defects? Metabolism 1994; 43:1475-1480.
14. Wald NJ, Hackshaw AK, Stone R, Sourial NA. Blood folic acid and vitamin B12 in relation to neural tube defects. Br J Obstet Gynaecol 1996; 103:319-324.
15. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM. Homocysteine metabolism in pregnancies complicated by neuraltube defects. Lancet 1995; 345:149-151.
16. Leclerc D, Campeau E, Goyette P, Adjalla CE, Christensen B, Ross M, et al. Human methionine synthase: cDNA cloning and identification of mutations in patients of the cblG complementation group of folate/ cobalamin disorders. Human Mol Genet 1996; 5:1867-1874.
17. Gulati S, Baker P, Li YN, Fowler B, Kruger W, Brody LC, Banerjee R. Defects in human methionine synthase in cblG patients. Human Mol Genet 1996; 5:1859-1865.
18. DHHS, FDA. Food standards: amendment of standards of identity for enriched grain products to require addition of folic acid. Federal Register 1996; 61: 8781-8807.
19. Wald N, Bower C. Folic acid and the prevention of neural tube defects. BMJ 1995; 310:1019-1020.
20. DHHS, FDA. Food additives permitted for direct addition to food for human consumption; folic acid (folacin). Federal Register 1993; 58: 53314-53315.
21. Daly LE, Kirke PN, Molloy A, Weir DG, Scott JM. Folate levels and neural tube defects, implications for prevention. JAMA 1995; 274:1696-1702.
22. Daly S, Mills JL, Molloy AM, Conley M, Lee YJ, Kirke PN, et al. Minimum •• effective dose of folic acid for food fortification to prevent neural tube defects. Lancet 1997; 350:1666-1669. This study suggests that safe doses of folic acid can be added to food and will result in a reduction in NTDs.
23. Hook EB, Czeizal AE. Can terathanasia explain the protective effect of • folic acid supplementation on birth defects? Lancet 1997; 350:513-515. This study raises the possibilty of an association between folic acid and miscarriage.
24. Warkany J. Terathanasia. Teratology 1978; 17:187-192.
25. Cziezal AE, Dudas I, Metneki J. Pregnancy outcomes in a randomized controlled trial of periconceptional multivitamin supplementation: final report. Arch Gynecol Obstet 1994; 255:131-139.
26. Ward N, Hackshaw A. Folic acid and prevention of neural-tube defects •• [letter]. Lancet 1997; 350:665. An excellent letter arguing against an association of folic acid with miscarriage.
27. Wild J, Sutcliffe M, Schorah CJ, Levene MI. Prevention of neural tube defects. Lancet 1997; 350:30-31.
28. Hurren C, Thorpe L, Veltman M, Fitzimon K, Elliott K. Folic acid and prevention of neural-tube defects [letter]. Lancet 1997; 350:664.
29. Harlap S, Kost K, Forrest JD. Preventing pregnancy, protecting health: new look at birth control choices in the United States. New York: The Alan Gutmacher Institute; 1991. p. 33.